

Title: Pretreatment CTP collateral parameters predict good outcomes in successfully recanalized middle cerebral artery distal medium vessel occlusions

Vivek Yedavalli, MD, MS¹, Omar Hamam, MBBS¹, Meisam Hoseinyazdi, MD¹, Elisabeth Breese Marsh, MD², Raf Llinas, MD,² Victor Urrutia, MD,² Richard Leigh, MD,² Fernando Gonzalez, MD,³ Risheng Xu, MD, PhD,³ Justin Caplan, MD³, Judy Huang, MD³, Hanzhang Lu, PhD¹, Max Wintermark, MD, MS, MBA⁴, Jeremy Heit, MD, PhD⁵, Adrien Guenego, MD, PhD,⁶ Greg Albers, MD⁶, Kambiz Nael, MD⁸, Argye Hillis, MD².

¹Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine

²Department of Neurology, Johns Hopkins School of Medicine

³Department of Neurosurgery, Johns Hopkins School of Medicine

⁴Department of Radiology, University of Texas MD Anderson

⁵Department of Radiology, Stanford University School of Medicine

⁶Department of Radiology, Université libre de Bruxelles

⁷Department of Neurology, Stanford University School of Medicine

⁸Department of Radiology, David Geffen UCLA School of Medicine

Short Title: CTP collateral parameters predict outcomes in DMVOs

Corresponding Author:

Vivek Yedavalli, MD, MS (First and Corresponding Author)

Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine

Phipps B112-D

Baltimore, MD 21287

Vyedaval@jhmi.edu

Key words: Acute Ischemic Stroke, Medium Vessel Occlusion, Perfusion Imaging, CT

Perfusion, Collateral Imaging

Total Word Count: 3754

Abstract:

Background: Distal medium vessel occlusions (DMVOs) account for a large percentage of vessel occlusions resulting in acute ischemic stroke (AIS) with disabling symptoms. We aim to assess whether pretreatment CT Perfusion collateral status (CS) parameters can serve as imaging biomarkers for good clinical outcomes prediction in successfully recanalized middle cerebral artery (MCA) DMVOs.

Methods: We performed a retrospective analysis of consecutive patients with AIS secondary to primary MCA-DMVOs who were successfully recanalized by mechanical thrombectomy (MT) defined as modified thrombolysis in cerebral infarction (mTICI) 2b, 2c, or 3. We evaluated the association between cerebral blood volume (CBV) index and hypoperfusion intensity ratio (HIR) independently with good clinical outcomes (modified Rankin score (mRS) 0-2) using Spearman rank correlation, logistic regression, and ROC analyses.

Results: From 8/22/2018 to 10/18/2022, 60 consecutive patients met our inclusion criteria (mean age 71.2 +/- 13.9 years old [mean+SD], 35 female). CBV index ($r = -0.693$, $p < 0.001$) and HIR (0.687, $p < 0.001$) strongly correlated with 90-day mRS. A CBV index ≥ 0.7 ((OR 2.27 [6.94 - 21.23], $p = 0.001$)) and absence of prior stroke (0.13 [0.33 - 0.86]), $p = 0.024$) were independently associated with good outcomes. ROC analysis demonstrated good performance of CBV Index in predicting good 90-day mRS (AUC 0.73, $p = 0.003$) with a threshold of 0.7 for optimal sensitivity (71% [52.0-85.8%]) and specificity (76% [54.9 - 90.6%]). HIR also demonstrated adequate performance in predicting good 90-day mRS (AUC 0.77, $p = 0.001$) with a threshold of 0.3 for optimal sensitivity (64.5% [45.4-80.8%]) and specificity (76.0% [54.9 - 90.6%]).

Conclusions: A CBV index ≥ 0.7 and HIR < 0.3 are independently associated with good clinical outcomes in our cohort of AIS caused by MCA-DMVOs that were successfully treated with MT.

Non-standard Abbreviations and Acronyms: Distal medium vessel occlusions = DMVOs, acute ischemic stroke = AIS, CT Perfusion = CTP, CT angiography = CTA, non-contrast CT = NCCT, collateral status = CS, middle cerebral artery = MCA, mechanical thrombectomy = MT, modified thrombolysis in cerebral infarction = mTICI, cerebral blood volume = CBV, hypoperfusion intensity ratio = HIR, modified rankin score = mRS, anterior cerebral artery = ACA, large vessel occlusion = LVO, time-to-maximum = Tmax, NIH stroke scale (NIHSS), hemorrhagic transformation = HT, intravenous tissue plasminogen activator = IV tPA, Alberta Stroke Program Early CT Score = ASPECTS, kilovoltage peak = kVp, milliamperere-seconds = mAs, body mass index = BMI, systolic blood pressure = SBP, diastolic blood pressure = DBP, heart rate = HR, respiratory rate = RR.

Introduction:

Distal medium vessel occlusions (DMVOs) - defined as M2-M4 segments of the middle cerebral artery (MCA), anterior cerebral artery (ACA) segments and vertebrobasilar branches - are thought to represent 25-40% of acute ischemic stroke (AIS) and can result in disabling symptoms¹. The current standard of care treatment for AIS caused by DMVOs is IV thrombolysis but fails to successfully recanalize DMVOs in up to two thirds of patients¹. With the recent technological advances, DMVOs are now increasingly being treated with mechanical thrombectomy (MT) despite current lack of consensus on guidelines².

Robust collaterals have been shown to predict good outcomes in large vessel occlusions (LVOs), but the effect of collateral status (CS) on DMVOs is still an area of ongoing research. Although CT angiography-based CS grading can be performed, there is significant variability amongst readers, necessitating automated quantitative pretreatment CT perfusion (CTP) CS assessments^{3,4}. The cerebral blood volume (CBV) Index – defined as the mean rCBV obtained by dividing the average of all CBV values from the time-to-maximum (Tmax) > 6 s region within the ischemic hemisphere by the average of all CBV values from all tissue with Tmax ≤ 4 s⁵ - and the hypoperfusion intensity ratio (HIR) - defined as time to maximum (Tmax) greater than 10 seconds volume divided by the Tmax greater than 6 second volume⁶⁻⁸ - have both been previously validated as reliable quantitative CS parameters, particularly for middle cerebral artery (MCA) LVOs. Prior LVO studies have reported thresholds of greater than 0.8 for CBV index⁹ and approximately 0.4 for HIR⁸, where patients with greater than 0.8 or HIR less than 0.4 have good CS. However, despite being established in LVOs, no studies to our knowledge have

assessed the optimal CBV Index threshold for MCA-DMVOs. Furthermore, the optimal threshold for HIR in MCA-DMVOs still remains underexplored.

Therefore, the primary aim of our study was to establish a threshold for CBV Index in patients with AIS due to primary MCA-DMVOs who were successfully recanalized by MT for clinical outcomes prediction. We hypothesize that the LVO threshold of approximately 0.8 for CBV index still applies to DMVOs. Our secondary aim is to also determine the predictive value of HIR in the same setting with comparison to CBV Index in order to assess the value of each CS parameter in the same cohort. For this aim, we hypothesize that a more restrictive threshold compared to the LVO threshold of 0.4 is optimal due to the longer transit time to the affected tissue. Specifically, we postulate that the previously suggested threshold of 0.3¹⁰ is optimal.

Methods:

Population and Study Design:

In this retrospective study, we identified consecutive patients from two comprehensive stroke centers within the Johns Hopkins Medical Enterprise (Johns Hopkins Hospital - East Baltimore and Bayview Medical Campus) from 8/22/2018 to 10/18/2022 in a continuously maintained database. This study was approved through the Johns Hopkins School of Medicine institutional review board (JHU-IRB00269637) and follows the STROBE checklist guidelines as an observational study¹¹.

The inclusion criteria for this study were as follows: a) MT triage within 24 hours of symptom onset or last known well; b) diagnostically adequate multimodal pretreatment CT imaging including NCCT, CTA, and CTP; c) AIS due to a CT angiography (CTA) confirmed MCA-DMVO, specifically including M2-M4 segments of the MCA as defined by Saver et al¹; and d) successful recanalization by MT defined as modified thrombolysis in cerebral infarction (mTICI) 2b or 3.

The study was conducted in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act (HIPAA). Informed consent was waived by the institutional review boards given the retrospective study design.

The decisions to administer intravenous tissue plasminogen activator (IV tPA) and/or perform MT were made on an individual basis based on consensus stroke team evaluation per our institution protocols and were controlled for in our analyses.

Data Collection:

Baseline and clinical data were collected through electronic records and stroke center databases for each patient included demographics, risk factors for AIS (including diabetes mellitus, hypertension, coronary artery disease, atrial fibrillation), admission glucose, admission NIH stroke scale (admission NIHSS), Alberta Stroke Program Early CT Score (ASPECTS), site of occlusion, and laterality of occlusion, and IV thrombolysis administration. Additional collected parameters included number of passes, recanalization time, mTICI score; presence of complication such as hemorrhagic transformation (HT) as defined by the ECASS trial. Patients

were subsequently grouped into good and poor CS based on the statistically determined optimal CBV threshold (please see below).

Imaging Analysis:

The ASPECTS scores were calculated on non-contrast CT (NCCT) and baseline CTAs were reviewed for presence and site of DMVO by an experienced neuroradiologist (VSY, 6 years of experience). The same neuroradiologist assessed the diagnostic adequacy of the CTPs where only those deemed diagnostic adequate were included in the study.

Imaging parameters:

NCCT: NCCT is performed in a helical mode at 5 mm slice thickness with 0.75 mm; reconstructions (120 kilovoltage peak (kVp), 365 milliamper-second (mAs), Rotation Time 1 second, Acquisition Time 6 - 8 seconds, Collimation 128 x 0.6 mm, Pitch Value 0.55, Scan Direction Craniocaudal).

CTA: The CTA of the head and neck is performed with non-ionic iodinated contrast with 50-70 ml injected at 5-6 ml/second from the aortic arch through the vertex using a bolus triggered method at 3 mm slice thickness with 0.75 mm reconstructions. The CTA parameters are as follows: 90/150 kVp with an Sn filter, Quality Reference mAs 180, Rotation Time 0.25 seconds, Average Acquisition Time 3-5 seconds, Collimation 128 x 0.6 mm, Pitch Value 0.7, Scan Direction Craniocaudal.

CTP: CTP is then performed with injection of 50 ml non-ionic iodinated contrast with a 30 ml saline flush at 5-6 ml/second with anatomic coverage of 70-100 mm at 5 mm slice thickness. Parameters as follows: 70 kVP, 200 Effective mAs, Rotation Time 0.25 seconds, Average Acquisition Time 60 seconds, Collimation 48 x 1.2 mm, Pitch Value 0.7, 4D Range 114 mm x 1.5 seconds, Scan Direction Craniocaudal. CTP images are then post-processed using RAPID commercial software (IschemaView, Menlo Park) for generating Tmax maps, from which the HIR and CBV Index are calculated.

Angiographic Assessment:

The pre-MT DSA collateral assessment was performed by two experienced neuroradiologists (MH and VSY, 3 and 6 years of experience respectively) using the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) criteria¹². Any discrepancies were assessed with a final score based on consensus evaluation. Grades 3 and 4 were categorized as good CS. Although Grade 2 is considered moderate CS, it was included in the poor CS group for dichotomized analysis.

The mTICI score was determined by the performing neurointerventionalist at the time of the procedure.

Clinical Outcomes Assessment:

Modified Rankin scores at discharge and 90 days (90 day mRS) in addition to discharge NIHSS were determined by a stroke neurologist or certified nurse practitioner.

Outcome Measures:

The primary outcomes were good clinical outcomes defined as 90-day mRS 0-2. The secondary outcomes included excellent outcomes (90-day mRS 0-1), discharge mRS, discharge NIHSS, and NIHSS shift (defined as the difference between discharge and admission NIHSS).

Statistical analysis:

The collected data were coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 28.0, IBM Corp., Chicago, USA, 2021. Quantitative data were tested for normality using Shapiro-Wilk test, then if normally distributed described as mean±SD (standard deviation) as well as minimum and maximum of the range. If data were not normally distributed, they were described as Median (1st–3rd Interquartiles) as well as minimum and maximum then compared using Mann Whitney test. Correlations between HIR and CBV Index as well as CBV Index with DSA CS and 90-day mRS were assessed by Spearman rank correlation. Receiver operating characteristics (ROC) curve was used to evaluate the performance of HIR and CBV Index where the optimal thresholds to predict 90-day mRS of 0-2 based on highest sensitivity and specificity were determined. Multivariate logistic regression analyses were also performed to assess the association of CBV index with 90-day mRS. Patients were then grouped based on the determined CBV optimal threshold. The level of significance taken at P value ≤ 0.050 was significant, otherwise was non-significant.

Results:

From 8/22/2018 to 10/18/2022, we identified 147 consecutive patients with AIS due to an MCA-DMVO. Of these 147 patients, 60 patients (mean age 71.2 +- 13.9 years old [mean+-SD], 35

female) met the inclusion criteria and were included in this study. In total, 56 out of the 60 patients had available 90-day mRS. All patients had discharge mRS and discharge NIHSS available. Please see Table 1 for demographic information.

Of the 60 patients, 51 had M2 occlusions (51/60, 85%), 6 had M3s (6/60, 10%), and 3 had M4s (3/60, 5%). See Table 1.

Nineteen patients received IV thrombolysis (19/60, 31.7%) prior to MT. Forty-six (46/60, 76.7%) had pretreatment DSA that was adequate for CS assessment. Forty-three patients achieved mTICI 3 recanalization (43/60, 71.7%). Hemorrhagic transformation of any subtype was found in 15 patients (15/60, 25%). A higher percentage of moderate and good CS based on DSA were found in the $CBV \geq 0.7$ group (4/6 vs 2/6, grade 2 and 14/20 vs 6/20, grade 3; $p = 0.004$) compared to the $CBV < 0.7$ group. Moreover, a higher percentage of poor CS based on DSA was found in the $CBV < 0.7$ group (4/4 vs 0.4 grade 0; 6/6 vs 0/6 grade 1; $p = 0.004$) versus the $CBV \geq 0.7$ group. Based on dichotomized DSA CS assessment, a higher percentage of good CS patients (19/30 vs 11/30) and a lower percentage of poor CS patients (4/16 vs 12/16) were also seen in the $CBV \geq 0.7$ group ($p = 0.013$). HIR was also lower in the $CBV \geq 0.7$ group (0.3 [median, IQR] [0.0-5.0] vs 0.5 [0.3-0.6; $p = 0.001$]). See Table 2.

Outcomes analysis revealed significantly lower 90 day mRS ([median, IQR] 1.0 [0.0-2.0] vs 4.5 [3.0 - 6.0], $p < 0.001$), discharge mRS (2.0 [2.0-3.0] vs 4.0 [3.0 - 5.0], $p < 0.001$), and discharge NIHSS (2.0 [1.0-5.0] vs 6.0 [2.0 - 12.0], $p = 0.001$) in the $CBV \geq 0.7$ group. A larger favorable

NIHSS shift was also found in the CBV ≥ 0.7 group (-10.5 [-16.0- -4.0] vs -3.0 [-6.0 - 3.0], $p < 0.001$). Please see Table 2 for details.

Correlation analysis:

CBV Index demonstrated a strong inverse correlation with 90-day mRS (-0.693, $p < 0.001$) and moderate inverse correlation with HIR (-0.494, $p < 0.001$). HIR also demonstrated a strong positive correlation with 90-day mRS (0.687, $p < 0.001$). CBV Index nor HIR were significantly correlated with DSA CS assessment. Please see Table 3.

ROC analysis:

ROC analysis demonstrated adequate performance of CBV Index in predicting good 90-day mRS (AUC 0.73, $p = 0.003$) with a threshold of 0.7 for optimal sensitivity (71% [52.0-85.8%]) and specificity (76% [54.9 - 90.6%]). CBV index also predicted excellent 90 day mRS (AUC 0.73, $p = 0.003$).

HIR also demonstrated good performance in predicting good 90-day mRS (AUC 0.77, $p = 0.001$) with a threshold of 0.3 for optimal sensitivity (64.5% [45.4-80.8%]) and specificity (76.0% [54.9 - 90.6%]). HIR also predicted excellent 90-day mRS (AUC 0.741, $p = 0.002$). Please see Figure 1.

No significant differences were noted between the diagnostic performances of the CBV index and HIR thresholds with respect to predicting good 90-day mRS ($p = 0.558$). Please see Table 4.

Multivariate regression analysis:

A CBV index of ≥ 0.7 (OR 2.27 [6.94 - 21.23], $p = 0.001$) was significantly associated with good outcomes. Furthermore, prior stroke (0.13 [0.33 - 0.86]), $p = 0.024$) was inversely associated with good outcomes.

Discussion:

In this study, we identify CBV index and HIR thresholds that predict good outcomes after thrombectomy treatment of MCA-DMVOs. We also demonstrate that a CBV index ≥ 0.7 is an independent predictor of good outcomes in this group of patients. This is the first study to our knowledge to determine a CBV index threshold for successfully recanalized AIS patients with DMVOs.

Although the current standard of care for DMVOs is IV thrombolysis, actual practice is increasingly using MT since IV thrombolysis fails to achieve recanalization in up to half of patients¹³. The advancements in endovascular technology have allowed for better navigation of these smaller caliber and often tortuous vessels. Several studies have demonstrated feasibility and safety of attempting MT in DMVOs^{1,2,13,14}, leading to an increased number of these patients being treated with MT.

In light of these advances in intervention, the effect of CS in DMVOs has become more relevant yet requires further investigation. As an established biomarker of infarct growth and outcomes in LVOs⁷, it stands to reason that CS similarly influences outcomes in DMVOs as well. Pretreatment CTP quantitative assessments with CBV index^{5,9,15} and HIR⁶⁻⁸ have been established as imaging biomarkers of CS in LVOs. However, due to the smaller volume of

affected tissue and the longer transit to reach these regions, the same LVO thresholds may not apply to DMVOs, which is the main purpose of our investigation.

As an indicator of the relative blood volume within critically hypoperfused tissue, CBV index is thought to represent an indirect compensatory response to the acute occlusion through collateralization. Our results indicate that a threshold of 0.7 where a pretreatment CBV index of 0.7 or greater predicts good clinical outcomes. This threshold is lower than the established LVO threshold of greater than 0.8 for 24-hour infarct volume prediction⁹. In direct comparison with respect to DMVOs, the 0.7 threshold is more accurate (73.2% versus 60.7%) and more sensitive (71.0% versus 35.5%) than 0.8, although less specific (76% versus 92%) in predicting good clinical outcomes. We postulate that the lower CBV index for MCA-DMVOs determined in our study is due to the smaller area of affected tissue where, where compared to LVOs, a less robust compensatory response may suffice to maintain tissue viability.

Interestingly, we did not find a correlation between DSA and both CBV index and HIR, respectively. However, we found a strong inverse correlation between CBV index and 90-day mRS in addition to a strong direct correlation between HIR and 90-day mRS. This discordance between both CS parameters' correlations with 90-day mRS and DSA may be due to a smaller sample of patients with DSA CS assessments. In our cohort, 46 patients (46/60, 76.7%) had DSAs that were imaged long enough to perform adequate CS assessments. Furthermore, despite DSA being considered the reference standard for CS assessment, prior studies are mixed on the robustness of DSA CS in predicting functional outcomes^{3,16,17}. It is possible that both CS parameters capture a compensatory component of CS that may translate completely to DSA but is reflected with subsequent clinical outcomes.

We also assessed the value of HIR as a predictive outcomes measure in successfully recanalized DMVOs. HIR is a well-established CS imaging biomarker in LVOs where a 0.4 threshold has been optimal⁶⁻⁸. LVOs patients with an HIR of less than 0.4, thought to represent good CS, has been correlated with good DSA collaterals in M1 occlusions⁶, validated for transferring patients for MT⁸, and predictive of infarct growth rate and clinical outcomes⁷ as well as post MT HT¹⁸. However, the role HIR plays in DMVOs is still being investigated.

Guenego et al most recently concluded that an HIR of less than 0.3 was associated with good CS and predicted less infarct growth in successfully recanalized DMVO cohort of 40 patients¹⁰. They also found that patients with an HIR equal to or greater than 0.3 had unfavorable outcomes on univariate analysis. However, this did not persist on multivariate analysis¹⁰. Our results are concordant with Guenego et al where we further validate the threshold of 0.3. In our cohort, patients with an HIR less than 0.3 predicted good and excellent outcomes, even doing so slightly superior to CBV index, although the difference was not significant ($p = 0.558$). Our study also has some notable differences compared to Guenego et al. First, our study has a larger sample size of 60 patients. Our analysis also focused on directly predicting clinical outcomes as opposed to infarct growth as a clinical outcome surrogate. In comparison to the LVO threshold of 0.4, the 0.3 threshold was slightly more accurate (69.6% versus 67.9%) and more specific (76.0% versus 68.0%), although less sensitive (64.5% versus 67.7%) in predicting good clinical outcomes. We hypothesize that this lower threshold for HIR compared to the LVO threshold of 0.4 is likely due to longer transit time to reach the affected region, necessitating a more restrictive threshold.

In addition to our CS parameter assessment, we also report that a history of prior stroke decreases the likelihood of good outcomes in these patients. Prior stroke as a predictive

biomarker is underexplored within this patient population. In a study assessing medium vessel occlusions with discrepant infarct patterns, Ospel et al found a history of prior stroke in 16.4% (43/262) of patients in their cohort¹⁹. Our cohort had a substantially higher percentage of patients with prior stroke (58.3%, 35/60). The difference in sample size may be the reason for this discrepancy with Ospel et al. Nevertheless, prior stroke is a well-established risk factor for stroke recurrence of all types²⁰⁻²² and, for that reason, it is understandable that a similar trend may also apply to the MCA-DMVO population. This may be an area of future research with larger studies.

Our study has several limitations. Firstly, it is inherently limited by its retrospective design. Secondly, we focused on only MCA-DMVOs with a predominance of M2 occlusions, which may introduce a bias. The M2 occlusion predominance is most likely due to the relative proximity of the vessel, making these occlusions more amenable to MT. Thirdly, our analysis is restricted to use of one commercial software platform, which may limit generalizability. Nevertheless, our study is strengthened by an adequate sample size of 60, given the stringent inclusion criteria of successfully recanalized MCA-DMVOs with MT. Our cohort consists of two comprehensive stroke centers serving different demographics, therefore improving generalizability.

In conclusion, the use of automated pretreatment CTP CS measures may have promise in everyday clinical practice. Currently, to our knowledge, no threshold for CBV index in the setting of DMVOs exists. Moreover, the utility of HIR in DMVOs still requires additional exploration. Our study demonstrates that, in comparison to LVO thresholds, a lower CBV index and a more restrictive HIR are associated with improved clinical outcomes in successfully recanalized MCA-DMVO patients. Given the prevalence of DMVOs, these thresholds have potential utility in everyday clinical practice as additional predictive imaging biomarkers in this

group. Nevertheless, larger scale studies must be performed to further assess the strength of our results.

Acknowledgements: None

Sources of Funding: None

Disclosures: Drs. Jeremy Heit and Vivek Yedavalli disclose roles as consultants for RAPID (iSchemaView, Menlo Park, CA). Dr. Greg Albers is the co-founder of RAPID.

References:

1. Saver JL, Chapot R, Agid R, Hassan AE, Jadhav AP, Liebeskind DS, Lobotesis K, Meila D, Meyer L, Raphaeli G, et al. Thrombectomy for Distal, Medium Vessel Occlusions: A Consensus Statement on Present Knowledge and Promising Directions. *Stroke*. 2020; 51:2872–2884.
2. Guenego A, Mine B, Bonnet T, Elens S, Vazquez Suarez J, Jodaitis L, Ligoit N, Naeije G, Lubicz B. Thrombectomy for distal medium vessel occlusion with a new generation of Stent retriever (Tiger retriever 13). *Interventional Neuroradiology*. 2022;28(4):444-454.
3. Kauw F, Dankbaar JW, Martin BW, Ding VY, Boothroyd DB, van Ommen F, de Jong HW, Kappelle LJ, Velthuis BK, Heit JJ, Wintermark M. Collateral status in ischemic stroke: a comparison of computed tomography angiography, computed tomography perfusion, and

- digital subtraction angiography. *Journal of computer assisted tomography*. 2020;44(6):984.
4. Wolff L, Su J, Van Loon D, van Es A, van Doormaal PJ, Majoie C, van Zwam W, Dippel D, van der Lugt A, van Walsum T, MR CLEAN investigators. Inter-rater reliability for assessing intracranial collaterals in patients with acute ischemic stroke: comparing 29 raters and an artificial intelligence-based software. *Neuroradiology*. 2022;64(12):2277-2284.
5. Arenillas JF, Cortijo E, García-Bermejo P, Levy EI, Jahan R, Liebeskind D, Goyal M, Saver JL, Albers GW. Relative cerebral blood volume is associated with collateral status and infarct growth in stroke patients in SWIFT PRIME. *Journal of Cerebral Blood Flow & Metabolism*. 2018;38(10):1839-1847.
6. Guenego A, Fahed R, Albers GW, Kuraitis G, Sussman ES, Martin BW, Marcellus DG, Olivot JM, Marks MP, Lansberg MG, Wintermark M. Hypoperfusion intensity ratio correlates with angiographic collaterals in acute ischaemic stroke with M1 occlusion. *European Journal of Neurology*. 2020;27(5):864-870.
7. Olivot JM, Mlynash M, Inoue M, Marks MP, Wheeler HM, Kemp S, Straka M, Zaharchuk G, Bammer R, Lansberg MG, Albers GW. Hypoperfusion intensity ratio predicts infarct progression and functional outcome in the DEFUSE 2 Cohort. *Stroke*. 2014;45(4):1018-1023.
8. Guenego A, Marcellus DG, Martin BW, Christensen S, Albers GW, Lansberg MG, Marks MP, Wintermark M, Heit JJ. Hypoperfusion intensity ratio is correlated with patient eligibility for thrombectomy. *Stroke*. 2019;50(4):917-922.
9. Rao VL, Mlynash M, Christensen S, Yennu A, Kemp S, Zaharchuk G, Heit JJ, Marks MP, Lansberg MG, Albers GW. Collateral status contributes to differences between observed and predicted 24-h infarct volumes in DEFUSE 3. *Journal of Cerebral Blood Flow &*

Metabolism. 2020;40(10):1966-1974.

10. Guenego A, Farouki Y, Mine B, Bonnet T, Hulscher F, Wang M, Elens S, Vazquez Suarez J, Jodaitis L, Ligot N, Naeije G. Hypoperfusion intensity ratio predicts infarct growth after successful thrombectomy for distal medium vessel occlusion. *Clinical Neuroradiology*. 2022;32(3):849-856.
11. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. *European journal of clinical investigation*. 2010;40(1):35-53.
12. Liu L, Ding J, Leng X, Pu Y, Huang LA, Xu A, Wong KS, Wang X, Wang Y. Guidelines for evaluation and management of cerebral collateral circulation in ischaemic stroke 2017. *Stroke and vascular neurology*. 2018;3(3).
13. Saber H, Desai SM, Haussen D, Al-Bayati A, Majidi S, Mocco J, Hassan AE, Rajah G, Waqas M, Davies JM, Dornbos D. Endovascular therapy vs medical management for patients with acute stroke with medium vessel occlusion in the anterior circulation. *JAMA network open*. 2022;5(10): e2238154-e2238154.
14. Farouki Y, Bonnet T, Mine B, Hulscher F, Wang M, Elens S, Suarez JV, Jodaitis L, Ligot N, Naeije G, Walker G. First-pass effect predicts clinical outcome and infarct growth after thrombectomy for distal medium vessel occlusions. *Neurosurgery*. 2022;91(6):913-919.
15. MacLellan A, Mlynash M, Kemp S, Ortega-Gutierrez S, Heit JJ, Marks MP, Lansberg MG, Albers GW, DEFUSE 3 Investigators. Perfusion imaging collateral scores predict infarct growth in non-reperused DEFUSE 3 patients. *Journal of Stroke and Cerebrovascular Diseases*. 2022;31(1):106208.
16. Lu WZ, Lin HA, Hou SK, Bai CH, Lin SF. Diagnostic test accuracy of pretreatment collateral score in predicting stroke outcomes after intra-arterial endovascular

thrombectomy: a meta-analysis in DSA and CTA. *European Radiology*. 2022;32(9):6097-6107.

17. Van Den Wijngaard IR, Boiten J, Holswilder G, Algra A, Dippel DW, Velthuis BK, Wermer MJ, van Walderveen MA. Impact of collateral status evaluated by dynamic computed tomographic angiography on clinical outcome in patients with ischemic stroke. *Stroke*. 2015;46(12):3398-3404.
18. Winkelmeier L, Heit JJ, Adusumilli G, Geest V, Christensen S, Kniep H, Van Horn N, Steffen P, Bechstein M, Sporns P, Lansberg MG. Hypoperfusion intensity ratio is correlated with the risk of parenchymal hematoma after endovascular stroke treatment. *Stroke*. 2023 Jan;54(1):135-143.
19. Ospel JM, Cimflova P, Marko M, Mayank A, Hafeez M, Almekhlafi MA, Hill MD, Demchuk AM, Menon BK, Goyal M. Prevalence and outcomes of medium vessel occlusions with discrepant infarct patterns. *Stroke*. 2020;51(9):2817-2824.
20. Flach C, Muret W, Wolfe CD, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: a population-base cohort study. *Stroke*. 2020;51(8):2435-2444.
21. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. *Stroke*. 1994;25(2):333-337.
22. Kolmos M, Christoffersen L, Kruuse C. Recurrent ischemic stroke—a systematic review and meta-analysis. *Journal of Stroke and Cerebrovascular Diseases*. 2021;30(8):105935.

Tables

Table (1): Demographic, admission findings, and vessel breakdown according to optimal CBV index threshold

Variables	All cases (Total=60)	CBV Index based CS		p-value
		Good CS ≥ 0.7 (Total=30)	Poor CS < 0.7 (Total=30)	
Age (years)	71.2 \pm 13.9	73.3 \pm 15.2	69.0 \pm 12.4	\wedge 0.230
Sex	Female	35 (58.3%)	20 (66.7%)	#0.190
	Male	25 (41.7%)	10 (33.3%)	
Race	Black	34 (56.7%)	16 (53.3%)	§0.893
	White	24 (40.0%)	13 (43.3%)	
	Asian	2 (3.3%)	1 (3.3%)	
BMI (kg/m ²)	28.2 \pm 5.6	28.3 \pm 5.8	28.1 \pm 5.6	\wedge 0.932
Smoking	31 (51.7%)	15 (50.0%)	16 (53.3%)	#0.796
Alcohol	18 (30.0%)	7 (23.3%)	11 (36.7%)	#0.260
Hypertension	51 (85.0%)	25 (83.3%)	26 (86.7%)	§0.999
Dyslipidemia	38 (63.3%)	19 (63.3%)	19 (63.3%)	#0.999
Heart disease	20 (33.3%)	10 (33.3%)	10 (33.3%)	#0.999
Prior stroke / TIA	35 (58.3%)	16 (53.3%)	19 (63.3%)	#0.432
A-Fib	15 (25.0%)	8 (26.7%)	7 (23.3%)	#0.766
Glucose (mg/dL)	143.2 \pm 72.7	155.2 \pm 93.6	131.2 \pm 41.0	\wedge 0.204
BUN (mg/dL)	20.7 \pm 11.2	23.3 \pm 11.7	18.1 \pm 10.3	\wedge 0.071
Creatinine (mg/dL)	1.2 \pm 0.9	1.4 \pm 1.2	1.1 \pm 0.4	\wedge 0.287
Hemoglobin (gm/dL)	12.6 \pm 1.9	12.4 \pm 2.0	12.9 \pm 1.7	\wedge 0.219
WBC (x10 ³ /mL)	9.7 \pm 8.8	10.9 \pm 12.1	8.4 \pm 2.8	\wedge 0.258

Platelets (x10³/mL)		242.6±85.3	254.8±82.4	230.4±87.7	^0.271
Admission NIHSS		10.5 (4.5–17.5)	9.0 (4.0–15.0)	13.5 (5.0–19.0)	□0.208
ASPECTS		9.0 (8.0–10.0)	9.0 (8.0–10.0)	9.0 (8.0–10.0)	□0.845
TOAST	Large artery atherosclerosis	10 (16.9%)	7 (23.3%)	3 (10.3%)	#0.115
	Cardioembolism	26 (44.1%)	15 (50.0%)	11 (37.9%)	
	Stroke of undetermined etiology	23 (39.0%)	8 (26.7%)	15 (51.7%)	
	M2	51 (85.0%)	28 (93.3%)	23 (76.7%)	
Segment	M3	6 (10.0%)	2 (6.7%)	4 (13.3%)	§0.115
	M4	3 (5.0%)	0 (0.0%)	3 (10.0%)	
	Left	32 (53.3%)	18 (60.0%)	14 (46.7%)	
Laterality	Right	28 (46.7%)	12 (40.0%)	16 (53.3%)	#0.301
	Proximal	31 (51.7%)	16 (53.3%)	15 (50.0%)	
Proximity	Mid	9 (15.0%)	5 (16.7%)	4 (13.3%)	§0.770
	Distal	19 (31.7%)	8 (26.7%)	11 (36.7%)	

BMI: Body mass index. Data presented as n (%), Mean±SD and Median (1st–3rd IQ). SBP:

Systolic blood pressure. DBP: Diastolic blood pressure. HR: Heart rate. RR: Respiratory rate.

*Significant (<0.050), §Fishers Exact test. #Chi square test. ^Independent t-test. □Mann-Whitney

test.

Table (2): Collateral parameters, interventional parameters, and clinical outcomes based on optimal CBV index threshold

Variables and Outcomes	All cases (Total=60)	CBV Index based CS		p-value
		Good CS ≥ 0.7 (Total=30)	Poor CS < 0.7 (Total=30)	
IV tpa	19 (31.7%)	11 (36.7%)	8 (26.7%)	#0.405
Anesthesia	4 (6.7%)	2 (6.7%)	2 (6.7%)	§0.999
Number of Passes	1.0 (1.0–2.0)	1.0 (1.0–1.0)	1.0 (1.0–2.0)	∩0.068
Last known well to Door (min.)	243.0 (63.0–594.0)	239.5 (75.0–596.0)	244.5 (61.0–568.0)	∩0.882
Symptom onset to Door (min.)	60.0 (48.0–144.0)	60.0 (47.0–146.0)	55.0 (48.0–65.0)	∩0.378
Door to CT (min.)	26.5 (15.5–37.0)	26.0 (15.0–37.0)	27.0 (16.0–42.0)	∩0.750
Last known well to CT (minutes)	272.0 (86.5–610.0)	269.5 (85.0–619.0)	281.5 (88.0–580.0)	∩0.882
Door to needle time (min.)	67.0 (55.0–115.0)	67.0 (55.0–87.0)	72.0 (55.0–125.5)	∩0.680
Door to groin puncture (min.)	148.5 (122.5–181.5)	143.5 (111.0–175.0)	152.5 (133.0–195.0)	∩0.169
Groin Puncture to First Pass (minutes)	25.0 (18.0–32.0)	24.0 (15.0–29.0)	26.0 (20.0–33.0)	∩0.231
Door to recanalization, (min.)	418.5 (243.0–732.0)	397.0 (258.0–764.0)	479.0 (210.0–715.0)	∩0.824
First Pass to recanalization, (min.)	5.0 (3.5–11.5)	5.0 (3.5–6.0)	8.0 (4.0–21.0)	∩0.078

Groin Puncture to recanalization (minutes)		32.5 (25.0–48.0)	30.0 (20.0–39.0)	40.0 (26.0–55.0)	□0.056
Hemorrhagic Transformation		15 (25.0%)	5 (16.7%)	10 (33.3%)	#0.136
mTICI score	2b	17 (26.6%)	9 (26.7%)	8 (26.7%)	0.999
	3	43 (71.7%)	22 (73.3%)	21 (70.0%)	
	0	4 (8.7%)	0 (0.0%)	4 (100%)	
	1	6 (13.0%)	0 (0.0%)	6 (100%)	
DSA grades	2	6 (13.0%)	4 (66.7%)	2 (33.3%)	§0.004*
	3	20 (43.5%)	14 (70.0%)	6 (30.0%)	
	4	10 (21.7%)	5 (50.0%)	5 (50.0%)	
DSA based CS	Good	30 (65.2%)	19 (63.3%)	11 (36.7%)	#0.013*
	Poor	16 (34.8%)	4 (25.0%)	12 (75.0%)	
HIR		0.4 (0.1–0.5)	0.3 (0.0–0.5)	0.5 (0.3–0.6)	□0.001*
NIHSS discharge		2.0 (1.0–6.0)	2.0 (1.0–5.0)	6.0 (2.0–12.0)	□0.001*
NIHSS shift		-6.0 (-13.0–0.0)	-10.5 (-16.0–4.0)	-3.0 (-6.0–3.0)	□<0.001*
Discharge mRS		3.0 (2.0–4.0)	2.0 (2.0–3.0)	4.0 (3.0–5.0)	□<0.001*
90-da7 mRS		2.0 (1.0–4.0)	1.0 (0.0–2.0)	4.5 (3.0–6.0)	□<0.001*

Data presented as n (%), Mean±SD and Median (1st–3rd IQ) *Significant (<0.050)

§Fishers Exact test. #Chi square test. ^Independent t-test. □Mann-Whitney test.

Table (3): Multivariate logistic regression for predicting good clinical outcomes

Factors	β	SE	p-value	OR (95% CI)
Good 90mRS				
Stroke	-1.10	0.49	0.024*	0.13 (0.33–0.86)
CBV index ≥ 0.7	1.94	0.57	0.001*	2.27 (6.94–21.23)

β : Regression coefficient, SE: Standard error, OR: Odds ratio, CI: Confidence interval,

*Significant (<0.050)

Table (4): CBV index and HIR correlations with other parameters

Factors	CBV index		HIR	
	r	p-value	r	p-value
90mRS	-0.693	<0.001*	0.687	<0.001*
DSA	0.236	0.114	-0.134	0.373
HIR	-0.494	<0.001*		

Spearman correlation. *Significant (<0.050)

Table (5): Diagnostic performance of CBV index and HIR in predicting good and excellent clinical outcomes

	AUC	p-value	Cut point	Sensitivity	Specificity	Accuracy	Youden's Index	PPV	NPV
90 d mRS (Good vs. Poor)									
HIR	0.770	0.001*	≤0.3	64.5%	76.0%	69.6%	40.5%	76.9%	63.3%
	0.648–			45.4–	54.9–	55.9–	16.8–	56.4–	43.9–80.1%
	0.893			80.8%	90.6%	81.2%	64.3%	91.0%	
CBV Index	0.003*	≥0.7	≤0.4	67.7%	68.0%	67.9%	35.7%	72.4%	63.0%
				48.6–	46.5–	54.0–	11.1–	52.8–	42.4–80.6%
				83.3%	85.1%	79.7%	60.3%	87.3%	
			0.730	71.0%	76.0%	73.2%	47.0%	78.6%	67.9%
			0.595–	52.0–	54.9–	59.7–	23.8–	59.0–	47.6–84.1%
			0.865	85.8%	90.6%	84.2%	70.1%	91.7%	
p-value (DeLong test between CBV index and HIR)	0.558	≥0.8	≥0.8	35.5%	92.0%	60.7%	27.5%	84.6%	53.5%
				19.2–	74.0–	46.8–	7.6%–	54.6–	37.7–68.8%
				54.6%	99.0%	73.5%	47.4%	98.1%	
90 d mRS (Excellent vs. Poor)									
HIR	0.741	<0.001*	≤0.3	69.6%	69.7%	69.6%	39.3%	61.5%	76.7%
	0.601–			47.1–	51.3–	55.9–	14.8–	40.6–	57.7–90.1%
	0.881			86.8%	84.4%	81.2%	63.7%	79.8%	
			≤0.4	69.6%	60.6%	64.3%	30.2%	55.2%	74.1%
				47.1–	42.1–	50.4–	5.0%–	35.7–	53.7–88.9%

				86.8%	77.1%	76.6%	55.3%	73.6%	
	0.733			73.9%	66.7%	69.6%	40.6%	60.7%	78.6%
CBV Index	0.596–	<0.001	≥ 0.7	51.6–	48.2–	55.9–	16.5–	40.6–	59.0–91.7%
	0.871	*		89.8%	82.0%	81.2%	64.7%	78.5%	
				39.1%	87.9%	67.9%	27.0%	69.2%	67.4%
			≥ 0.8	19.7–	71.8–	54.0–	4.2%–	38.6–	51.5–80.9%
				61.5%	96.6%	79.7%	49.9%	90.9%	
p-value									
(DeLong test	0.906								
between CBV									
index and HIR)									

AUC: Area under curve. *Significant (<0.050). PPV: Positive Predictive Value. NPV: Negative Predictive Value.

Figures




Figure (1): Receiver Operating Characteristics (ROC) curve for HIR and CBV in predicting good 90mRS

Table (1): Demographic, admission findings, and vessel breakdown according to optimal CBV index threshold

Variables	All cases (Total=60)	CBV Index based CS		p-value
		Good CS ≥ 0.7 (Total=30)	Poor CS < 0.7 (Total=30)	
Age (years)	71.2 \pm 13.9	73.3 \pm 15.2	69.0 \pm 12.4	\wedge 0.230
Sex	Female	35 (58.3%)	20 (66.7%)	#0.190
	Male	25 (41.7%)	10 (33.3%)	
Race	Black	34 (56.7%)	16 (53.3%)	§0.893
	White	24 (40.0%)	13 (43.3%)	
	Asian	2 (3.3%)	1 (3.3%)	
BMI (kg/m ²)	28.2 \pm 5.6	28.3 \pm 5.8	28.1 \pm 5.6	\wedge 0.932
Smoking	31 (51.7%)	15 (50.0%)	16 (53.3%)	#0.796
Alcohol	18 (30.0%)	7 (23.3%)	11 (36.7%)	#0.260
Hypertension	51 (85.0%)	25 (83.3%)	26 (86.7%)	§0.999
Dyslipidemia	38 (63.3%)	19 (63.3%)	19 (63.3%)	#0.999
Heart disease	20 (33.3%)	10 (33.3%)	10 (33.3%)	#0.999
Prior stroke / TIA	35 (58.3%)	16 (53.3%)	19 (63.3%)	#0.432
A-Fib	15 (25.0%)	8 (26.7%)	7 (23.3%)	#0.766
Glucose (mg/dL)	143.2 \pm 72.7	155.2 \pm 93.6	131.2 \pm 41.0	\wedge 0.204
BUN (mg/dL)	20.7 \pm 11.2	23.3 \pm 11.7	18.1 \pm 10.3	\wedge 0.071
Creatinine (mg/dL)	1.2 \pm 0.9	1.4 \pm 1.2	1.1 \pm 0.4	\wedge 0.287
Hemoglobin (gm/dL)	12.6 \pm 1.9	12.4 \pm 2.0	12.9 \pm 1.7	\wedge 0.219
WBC (x10 ³ /mL)	9.7 \pm 8.8	10.9 \pm 12.1	8.4 \pm 2.8	\wedge 0.258
Platelets (x10 ³ /mL)	242.6 \pm 85.3	254.8 \pm 82.4	230.4 \pm 87.7	\wedge 0.271
Admission NIHSS	10.5 (4.5–17.5)	9.0 (4.0–15.0)	13.5 (5.0–19.0)	◻0.208
ASPECTS	9.0 (8.0–10.0)	9.0 (8.0–10.0)	9.0 (8.0–10.0)	◻0.845
TOAST	Large artery atherosclerosis	10 (16.9%)	7 (23.3%)	#0.115
	Cardioembolism	26 (44.1%)	15 (50.0%)	
	Stroke of undetermined etiology	23 (39.0%)	8 (26.7%)	
Segment	M2	51 (85.0%)	28 (93.3%)	§0.115
	M3	6 (10.0%)	2 (6.7%)	
	M4	3 (5.0%)	0 (0.0%)	
Laterality	Left	32 (53.3%)	18 (60.0%)	#0.301
	Right	28 (46.7%)	12 (40.0%)	
Proximity	Proximal	31 (51.7%)	16 (53.3%)	§0.770
	Mid	9 (15.0%)	5 (16.7%)	
	Distal	19 (31.7%)	8 (26.7%)	

BMI: Body mass index. Data presented as n (%), Mean \pm SD and Median (1st–3rd IQ). SBP: Systolic blood pressure. DBP: Diastolic blood pressure. HR: Heart rate. RR: Respiratory rate. §Fishers Exact test. #Chi square test. \wedge Independent t-test. ◻Mann-Whitney test. *Significant (<0.050)

Table (2): Collateral parameters, interventional parameters, and clinical outcomes based on optimal CBV index threshold

Variables and Outcomes	All cases (Total=60)	CBV Index based CS		p-value
		Good CS ≥ 0.7 (Total=30)	Poor CS < 0.7 (Total=30)	
IV tpa	19 (31.7%)	11 (36.7%)	8 (26.7%)	#0.405
Anesthesia	4 (6.7%)	2 (6.7%)	2 (6.7%)	§0.999

Number of Passes		1.0 (1.0–2.0)	1.0 (1.0–1.0)	1.0 (1.0–2.0)	□0.068
Last known well to Door (min.)		243.0 (63.0–594.0)	239.5 (75.0–596.0)	244.5 (61.0–568.0)	□0.882
Symptom onset to Door (min.)		60.0 (48.0–144.0)	60.0 (47.0–146.0)	55.0 (48.0–65.0)	□0.378
Door to CT (min.)		26.5 (15.5–37.0)	26.0 (15.0–37.0)	27.0 (16.0–42.0)	□0.750
Last known well to CT (minutes)		272.0 (86.5–610.0)	269.5 (85.0–619.0)	281.5 (88.0–580.0)	□0.882
Door to needle time (min.)		67.0 (55.0–115.0)	67.0 (55.0–87.0)	72.0 (55.0–125.5)	□0.680
Door to groin puncture (min.)		148.5 (122.5–181.5)	143.5 (111.0–175.0)	152.5 (133.0–195.0)	□0.169
Groin Puncture to First Pass (minutes)		25.0 (18.0–32.0)	24.0 (15.0–29.0)	26.0 (20.0–33.0)	□0.231
Door to recanalization, (min.)		418.5 (243.0–732.0)	397.0 (258.0–764.0)	479.0 (210.0–715.0)	□0.824
First Pass to recanalization, (min.)		5.0 (3.5–11.5)	5.0 (3.5–6.0)	8.0 (4.0–21.0)	□0.078
Groin Puncture to recanalization (minutes)		32.5 (25.0–48.0)	30.0 (20.0–39.0)	40.0 (26.0–55.0)	□0.056
Hemorrhagic Transformation		15 (25.0%)	5 (16.7%)	10 (33.3%)	#0.136
mTICI score	2b	17 (26.6%)	9 (26.7%)	8 (26.7%)	0.999
	3	43 (71.7%)	22 (73.3%)	21 (70.0%)	
DSA grades	0	4 (8.7%)	0 (0.0%)	4 (100%)	§0.004*
	1	6 (13.0%)	0 (0.0%)	6 (100%)	
	2	6 (13.0%)	4 (66.7%)	2 (33.3%)	
	3	20 (43.5%)	14 (70.0%)	6 (30.0%)	
	4	10 (21.7%)	5 (50.0%)	5 (50.0%)	
DSA based CS	Good	30 (65.2%)	19 (63.3%)	11 (36.7%)	#0.013*
	Poor	16 (34.8%)	4 (25.0%)	12 (75.0%)	
HIR		0.4 (0.1–0.5)	0.3 (0.0–0.5)	0.5 (0.3–0.6)	□0.001*
NIHSS discharge		2.0 (1.0–6.0)	2.0 (1.0–5.0)	6.0 (2.0–12.0)	□0.001*
NIHSS shift		-6.0 (-13.0–0.0)	-10.5 (-16.0–4.0)	-3.0 (-6.0–3.0)	□<0.001*
Discharge mRS		3.0 (2.0–4.0)	2.0 (2.0–3.0)	4.0 (3.0–5.0)	□<0.001*
90-da7 mRS		2.0 (1.0–4.0)	1.0 (0.0–2.0)	4.5 (3.0–6.0)	□<0.001*

Data presented as n (%), Mean±SD and Median (1st–3rd IQ). §Fishers Exact test.

#Chi square test. ^Independent t-test. □Mann-Whitney test. *Significant (<0.050)

Table (3): Multivariate logistic regression for predicting good clinical outcomes

Factors	β	SE	p-value	OR (95% CI)
Good 90mRS				
Stroke	-1.10	0.49	0.024*	0.13 (0.33–0.86)
CBV index ≥0.7	1.94	0.57	0.001*	2.27 (6.94–21.23)

β : Regression coefficient, SE: Standard error, OR: Odds ratio, CI: Confidence interval, *significant

Table (4): CBV index and HIR correlations with other parameters

Factors	CBV index		HIR	
	r	p-value	r	p-value
90mRS	-0.693	<0.001*	0.687	<0.001*
DSA	0.236	0.114	-0.134	0.373
HIR	-0.494	<0.001*		

Spearman correlation. *Significant

Table (5): Diagnostic performance of CBV index and HIR in predicting good and excellent clinical outcomes

	AUC	p-value	Cut point	Sensitivity	Specificity	Accuracy	Youden's Index	PPV	NPV
90 d mRS (Good vs. Poor)									
HIR	0.770	0.001*	≤0.3	64.5%	76.0%	69.6%	40.5%	76.9%	63.3%
	0.648–0.893			45.4–80.8%	54.9–90.6%	55.9–81.2%	16.8–64.3%	56.4–91.0%	43.9–80.1%
			≤0.4	67.7%	68.0%	67.9%	35.7%	72.4%	63.0%
				48.6–83.3%	46.5–85.1%	54.0–79.7%	11.1–60.3%	52.8–87.3%	42.4–80.6%
CBV Index	0.730	0.003*	≥0.7	71.0%	76.0%	73.2%	47.0%	78.6%	67.9%
	0.595–0.865			52.0–85.8%	54.9–90.6%	59.7–84.2%	23.8–70.1%	59.0–91.7%	47.6–84.1%
			≥0.8	35.5%	92.0%	60.7%	27.5%	84.6%	53.5%
				19.2–54.6%	74.0–99.0%	46.8–73.5%	7.6%–47.4%	54.6–98.1%	37.7–68.8%
p-value (DeLong test between CBV index and HIR)	0.558								
90 d mRS (Excellent vs. Poor)									
HIR	0.741	<0.001*	≤0.3	69.6%	69.7%	69.6%	39.3%	61.5%	76.7%
	0.601–0.881			47.1–86.8%	51.3–84.4%	55.9–81.2%	14.8–63.7%	40.6–79.8%	57.7–90.1%
			≤0.4	69.6%	60.6%	64.3%	30.2%	55.2%	74.1%
				47.1–86.8%	42.1–77.1%	50.4–76.6%	5.0%–55.3%	35.7–73.6%	53.7–88.9%
CBV Index	0.733	<0.001*	≥0.7	73.9%	66.7%	69.6%	40.6%	60.7%	78.6%
	0.596–0.871			51.6–89.8%	48.2–82.0%	55.9–81.2%	16.5–64.7%	40.6–78.5%	59.0–91.7%
			≥0.8	39.1%	87.9%	67.9%	27.0%	69.2%	67.4%
				19.7–61.5%	71.8–96.6%	54.0–79.7%	4.2%–49.9%	38.6–90.9%	51.5–80.9%
p-value (DeLong test)	0.906								

between CBV index and HIR)									
----------------------------	--	--	--	--	--	--	--	--	--

AUC: Area under curve. *Significant (<0.050). PPV: Positive Predictive Value. NPV: Negative Predictive Value.




Figure (1): Receiver Operating Characteristics (ROC) curve for HIR and CBV in predicting good 90mRS




Figure (1): Receiver Operating Characteristics (ROC) curve for HIR and CBV in predicting good 90mRS